Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

October 1, 2026

Conditions
Chronic Low-back PainDegenerative Disc Disease
Interventions
DRUG

CELZ-201-DDT

Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

OTHER

Placebo

Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

Trial Locations (1)

33180

RECRUITING

Spine and Wellness Centers of America, Aventura

All Listed Sponsors
lead

Creative Medical Technology Holdings Inc

INDUSTRY